February 2026 Research Update

This month, studies comparing real-world surgical approaches mostly showed a practical message: the visible extent of cholesteatoma often steers which operation is chosen, but short-term outcomes like hearing and early recurrence did not clearly separate into a single "best" option across groups. In a large Japanese cohort, more mastoid extension led to different procedure choices, yet early recurrence and hearing outcomes were similar across extension categories. In smaller retrospective and prospective cohorts, hearing tended to improve after surgery, and some endoscopic-only series reported very good early follow-up results. [1] [2] [3]

In 527 operated ears staged using the Japan Otological Society system, higher mastoid-extension categories (M0 to M2) lined up with higher overall stage and changed which procedures were used, including less frequent use of transcanal endoscopic techniques as extension increased. Even so, short-term recurrence rates and postoperative hearing did not differ across M0, M1, and M2 in this report. For patients, this supports the idea that more extensive disease can mean a different operation without automatically meaning worse short-term hearing results. [1]

A separate retrospective cohort of 45 adults undergoing canal wall down mastoidectomy with ossiculoplasty reported improved air-conduction hearing and a smaller air-bone gap over time. The study did not find meaningful differences based on the type of reconstruction (TORP vs PORP), whether reconstruction was done at the same surgery or later, or whether mastoid obliteration was performed. This adds to the picture that several commonly used reconstruction strategies can lead to similar hearing results in routine care, at least within the limits of a small, non-randomized dataset. [2]

Two studies focused on endoscopic ear surgery from different angles, and together they describe both feasibility and early outcomes. In a Japanese multicenter prospective dataset covering several middle ear conditions, transcanal endoscopic ear surgery was used in 66% of cholesteatoma operations (331 of 500), showing it is common but not universal in current practice. In a single-center prospective series of 41 patients treated exclusively by an endoscopic transcanal approach, quality-of-life scores and hearing measures improved through 12 months, and MRI at 12 months found no residual or recurrent disease in that cohort. [4] [3]

For very deep skull-base disease, a small retrospective series described an inframeatal intradural retrosigmoid petrosectomy approach used for different petrous bone lesions, including invasive cholesteatoma. The authors reported gross total removal in most patients and one recurrence with follow-up up to 20 months, with one transient complication. This kind of report does not compare approaches, but it helps document what selected specialty centers are attempting for complex locations where surgical access is challenging. [5]

For patients and caregivers, these studies mainly add context rather than changing what anyone should do now. They show that surgeons often tailor the operation to where the cholesteatoma extends, and that short-term hearing outcomes can be similar across some surgical subgroups in observational data. The endoscopic studies add an early signal that many cholesteatoma surgeries can be done through the ear canal, and that selected patients may report better day-to-day ear-related quality of life after endoscopic-only surgery, but longer follow-up is still needed to know how well results hold over time. [1] [4] [3]

It also became a bit clearer what questions are still open. When studies report "no difference" between subgroups (for example, timing or type of reconstruction), that can mean several approaches perform similarly, but it can also reflect limited sample sizes and non-randomized choices. The most useful near-term takeaway is that research is increasingly tracking outcomes that matter to people, including hearing tests and patient-reported quality of life, rather than only surgical descriptions. [2] [3]

This month added two kinds of "big picture" evidence: one study looked at inherited differences in immune and inflammation genes in people with cholesteatoma, and another looked at whether cholesteatoma is seen more often in people with dementia. The genetics results pointed most strongly to genes that amplify ongoing inflammation, rather than genes that only start the immune response. The dementia analysis reported higher odds of dementia in people coded with cholesteatoma, but that link became less clear after the analysis accounted for surgical treatment. [6] [7]

In UK Biobank, a gene-based analysis across 678 people with cholesteatoma highlighted the largest differences in genetic risk scores in IL6, TREM1, IL1R1, IL1A, RAGE, and TNFA, among others. These genes are described as downstream "signal boosters" in inflammation, which fits with the idea of self-perpetuating inflammation in cholesteatoma rather than inflammation being driven only by initial triggers. This does not mean these genes determine who will get cholesteatoma, but it helps refine which immune pathways researchers are prioritizing. [6]

In the NIH All of Us dataset (396,194 adults), cholesteatoma and tympanic membrane perforation were each linked to higher odds of all-cause dementia in the main analysis, while otosclerosis was not. When the analysis added surgical treatment, the cholesteatoma-dementia estimate became smaller and was no longer statistically significant in this report. Because this was cross-sectional and based on diagnosis codes, it cannot tell whether ear disease contributes to dementia risk, whether dementia affects detection and care, or whether other shared factors drive both. [7]

For patients, these studies mainly provide early research clues rather than answers that change care today. The genetics study supports the idea that persistent inflammation may be part of why cholesteatoma can keep progressing, which may matter later if it helps scientists identify new targets for future therapies. The dementia study raises an important question about broader health connections, but it does not prove that cholesteatoma causes dementia, and the finding for cholesteatoma became less clear after accounting for surgery in the same dataset. [6] [7]

What remains uncertain is how these population-level signals translate to an individual person. Genetic risk scores are not used as routine tests for cholesteatoma, and the dementia analysis is a snapshot in time that cannot sort out direction or cause. The main value right now is that these datasets help researchers decide which questions to test next, including how inflammation pathways might be linked to disease persistence. [6] [7]

This month included several smaller or early-stage studies that are not ready to guide everyday decisions, but they show where research is trying to reduce uncertainty. One lab study tested whether a drug-like compound could reduce growth of keratin-producing cells. A CT-based anatomy study measured narrow spaces near critical structures to support planning for hearing-preserving surgery in difficult skull-base cases. Two case reports described practical diagnostic or follow-up observations in individual patients. [8] [9] [10] [11]

In a laboratory study using immortalized human keratinocytes, halofuginone reduced cell viability in a dose- and time-dependent way, with a lower IC50 at 48 hours than at 24 hours. This supports the idea that halofuginone could potentially modulate cholesteatoma-like epithelium, but the work did not test actual cholesteatoma tissue, did not study hearing safety, and cannot predict how a medication would behave in the ear. For patients, it is best understood as an early screening step that may or may not lead to future treatments. [8]

A CT measurement study described wide variation in the size and shape of tight recesses near the cochlea and carotid artery that can limit endoscopic access in massive petrous bone cholesteatoma surgery. The authors reported that a notable minority of samples had very small spaces that could restrict a 3 mm instrument, and they illustrated in one clinical case how preoperative measurements could inform dissection with cochlear preservation. This matters most for people facing complex skull-base surgery, where detailed anatomy can strongly influence what is feasible and what risks need planning around. [9]

Two case reports highlighted how variable cholesteatoma presentation and follow-up can be. One described external auditory canal cholesteatoma in a teenager with ear pain, drainage, and worsening hearing, with imaging showing bony erosion and symptom relief after excision. Another described a patient with prior canal wall-down surgery where performing a Valsalva maneuver during endoscopic exam moved keratin into view, helping confirm recurrence and assess its extent before revision surgery. [10] [11]

For patients and caregivers, this set of studies is mainly about building better tools for the future and documenting clinical observations that may help recognition. The lab findings around halofuginone do not translate into a treatment you can expect in clinic, but they help narrow down which compounds might be worth testing next in more realistic models. The CT-anatomy measurements support the idea that individualized anatomy can be a major factor in complex surgical planning, especially when surgeons aim to preserve hearing in difficult locations. [8] [9]

The case reports do not tell what will happen for most people, but they can make the range of real-life scenarios easier to picture. One shows that cholesteatoma can occur in the external ear canal and cause symptoms similar to other ear problems, with diagnosis confirmed after removal. The other suggests a simple in-clinic maneuver can sometimes make recurrent keratin more visible during follow-up exams, while also noting that the sign is not specific and its absence does not rule out recurrence. [10] [11]